NEUWAY Pharma GmbH signs License Agreement with University Zürich
NEUWAY Pharma and University Zurich enter license agreement for developing a treatment for PML
(firmenpresse) - Bonn, Zurich February 2015. University Zurich and NEUWAY Pharma GmbH, a German biotech start-up company, today announced that they have entered into a license agreement. Under the terms of this agreement NEUWAY will develop its technology to treat a rare but frequently fatal neurological disease called progessive multifocal leucoencephalopathy (PML).
Researchers at University Zurich found that NEUWAY’s engineered protein capsules (EPCs) may be used in the treatment of PML. EPCs have already been applied by clinical researchers at the university hospital of Zurich and found to enhance the immune response against the disease causing agent.
„ With NEUWAY’s EPCs we have a promising tool for the therapy of PML“, says Dr. Roland Martin, clinical researcher at university Zurich, „however further clinical studies will be needed to determine safety and efficacy of this treatment option“.
For NEUWAY, the license agreement opens an additional business field: „Our primary goal is the use of EPCs as drug delivery system. In preclinical studies we found that EPCs show a low or even no immunogenicity. The immune response however could be enhanced by modulators to use empty EPCs as vaccine also”, says Heiko Manninga, Managing Director at NEUWAY.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.
NEUWAY Pharma GmbH:
Press Contact:
Christine Kuhn, +49-(0)228-522198-0, kuhn(at)neuway.de
www.neuway.de
Datum: 03.02.2015 - 05:27 Uhr
Sprache: Deutsch
News-ID 1334356
Anzahl Zeichen: 0
contact information:
Contact person: Christine Kuhn
Town:
Bonn
Phone: 0228-5221980
Kategorie:
Pharmaceuticals & Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 543 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NEUWAY Pharma GmbH signs License Agreement with University Zürich
"
steht unter der journalistisch-redaktionellen Verantwortung von
NEUWAY Pharma GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
